PL2329848T5 - Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 - Google Patents

Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2

Info

Publication number: PL2329848T5
Authority: PL; Poland
Prior art keywords: lixisenatide; metformin; diabetes; therapy; add
Prior art date: 2009-11-13

Application number

PL09175877T

Other languages

English (en)

Other versions

PL2329848T3 (pl

Inventor

Louise Silvestre

Elisabeth Souhami

Xiaodan Wei

Original Assignee

Sanofi-Aventis Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-13

Filing date

2009-11-13

Publication date

2019-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41800749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2329848(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-13 Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh

2013-05-31 Publication of PL2329848T3 publication Critical patent/PL2329848T3/pl

2019-12-31 Publication of PL2329848T5 publication Critical patent/PL2329848T5/pl

Links

108010057186 Insulin Glargine Proteins 0.000 title 1
COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 title 1
XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
229960002869 insulin glargine Drugs 0.000 title 1
229960001093 lixisenatide Drugs 0.000 title 1
108010004367 lixisenatide Proteins 0.000 title 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
229960003105 metformin Drugs 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL09175877T 2009-11-13 2009-11-13 Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 PL2329848T5 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09175877.1A EP2329848B2 (en)	2009-11-13	2009-11-13	Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes

Publications (2)

Publication Number	Publication Date
PL2329848T3 PL2329848T3 (pl)	2013-05-31
PL2329848T5 true PL2329848T5 (pl)	2019-12-31

Family

ID=41800749

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09175877T PL2329848T5 (pl)	2009-11-13	2009-11-13	Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2

Country Status (11)

Country	Link
EP (1)	EP2329848B2 (pl)
CY (1)	CY1113755T1 (pl)
DK (1)	DK2329848T4 (pl)
ES (1)	ES2398012T5 (pl)
HR (1)	HRP20121029T4 (pl)
ME (1)	ME01546B (pl)
PL (1)	PL2329848T5 (pl)
PT (1)	PT2329848E (pl)
RS (1)	RS52629B2 (pl)
SI (1)	SI2329848T2 (pl)
SM (1)	SMT201300013B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3228320T3 (pl)	2008-10-17	2020-06-01	Sanofi-Aventis Deutschland Gmbh	Kombinacja insuliny i agonisty GLP-1
SI2554183T1 (en)	2009-11-13	2018-08-31	Sanofi-Aventis Deutschland Gmbh	A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine
DK2498801T3 (en)	2009-11-13	2018-05-07	Sanofi Aventis Deutschland	PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
KR101823320B1 (ko)	2010-08-30	2018-01-31	사노피-아벤티스 도이칠란트 게엠베하	제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
TW201236692A (en) *	2011-02-02	2012-09-16	Sanofi Aventis Deutschland	Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
DK2750699T3 (en)	2011-08-29	2015-10-26	Sanofi Aventis Deutschland	A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130296236A1 (en) *	2011-10-28	2013-11-07	Louise SILVESTRE	Treatment protocol of diabetes type 2
BR112015024659A8 (pt)	2013-04-03	2019-12-17	Sanofi Sa	formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação
US20140371141A1 (en) *	2013-06-17	2014-12-18	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TN2017000235A1 (en)	2014-12-12	2018-10-19	Sanofi Aventis Deutschland	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels

2009
- 2009-11-13 PL PL09175877T patent/PL2329848T5/pl unknown
- 2009-11-13 EP EP09175877.1A patent/EP2329848B2/en active Active
- 2009-11-13 ES ES09175877T patent/ES2398012T5/es active Active
- 2009-11-13 ME MEP-2012-147A patent/ME01546B/me unknown
- 2009-11-13 DK DK09175877.1T patent/DK2329848T4/da active
- 2009-11-13 PT PT91758771T patent/PT2329848E/pt unknown
- 2009-11-13 RS RS20120571 patent/RS52629B2/sr unknown
- 2009-11-13 SI SI200930473T patent/SI2329848T2/sl unknown
2012
- 2012-12-13 HR HRP20121029TT patent/HRP20121029T4/hr unknown
2013
- 2013-01-09 CY CY20131100022T patent/CY1113755T1/el unknown
- 2013-01-30 SM SM201300013T patent/SMT201300013B/xx unknown

Also Published As

Publication number	Publication date
CY1113755T1 (el)	2016-07-27
HRP20121029T1 (hr)	2013-01-31
SMT201300013B (it)	2013-03-08
EP2329848A1 (en)	2011-06-08
SI2329848T2 (sl)	2019-10-30
ES2398012T5 (es)	2020-02-26
SI2329848T1 (sl)	2013-02-28
EP2329848B2 (en)	2019-06-19
PL2329848T3 (pl)	2013-05-31
DK2329848T3 (da)	2013-02-04
RS52629B (en)	2013-06-28
EP2329848B1 (en)	2012-10-24
DK2329848T4 (da)	2019-09-09
ES2398012T3 (es)	2013-03-13
HRP20121029T4 (hr)	2019-10-18
ME01546B (me)	2014-04-20
PT2329848E (pt)	2013-01-23
RS52629B2 (sr)	2019-11-29

Similar Documents

Publication	Publication Date	Title
HRP20121029T1 (hr)	2013-01-31	Liksisenatid kao pomoä†na terapija uz inzulin glargin i metformin kod lijeäśenja dijabetesa tip 2
PT2324853E (pt)	2015-11-30	Lixisenatida como adjuvante da metformina no tratamento de diabetes do tipo 2
SI2707015T1 (sl)	2017-03-31	Liksisenatid kot dodatna terapija bazalnemu inzulinu pri sladkorni bolezni tipa 2
IL219945A (en)	2016-12-29	1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
IL209887A0 (en)	2011-02-28	Treatment for diabetes in patients inappropriate for metformin therapy
IL212903A0 (en)	2011-07-31	Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
IL250548A0 (en)	2017-03-30	Acetyl analogs of insulin that are resistant to protease and their use for the preparation of a drug for the treatment and prevention of diabetes
PL2707017T3 (pl)	2016-03-31	Liksisenatyd i metformina do leczenia cukrzycy typu 2
SI2379100T1 (sl)	2015-02-27	Zdravljenje hiperglikemije z GLP-1
EP2424507A4 (en)	2012-10-24	COMPOSITIONS AND METHODS FOR THE TREATMENT OF INSULIN AND DIABETES RESISTANCE
PL2133091T3 (pl)	2014-03-31	Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy
PT2611458T (pt)	2016-12-16	Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
EP2127665A4 (en)	2011-06-29	MEDICAL PREPARATION BASED ON EXENATIDE AND DALARGINE FOR THE TREATMENT OF PANCREATIC DIABETES
PT2459207E (pt)	2014-02-21	Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
ZA201105094B (en)	2012-03-28	Combination of insulin with triazine derivatives and its use for treating diabetes
GB0919603D0 (en)	2009-12-23	Use of thymosin beta-4 for treatment of type II diabetes
EG25982A (en)	2012-11-18	Painless insulin injecting pen
ZA201008998B (en)	2012-07-25	Treatment for diabetes in patients inappropriate for metformin therapy
EG27140A (en)	2015-08-09	Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
ZA200909123B (en)	2010-09-29	Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
GB0904271D0 (en)	2009-04-22	Treatment of diabetes and metabolic syndrome
GB0910904D0 (en)	2009-08-05	Treatment of diabetes and metabolic syndrome
GB0912906D0 (en)	2009-08-26	Treatment of diabetes and metabolic syndrome
SG10201601210YA (en)	2016-03-30	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
GB0802903D0 (en)	2008-03-26	Treatment of diabetes